ReviewCureus2026
Corticosteroid Taper Duration and Relapse Rate in Immune Checkpoint Inhibitor-Induced Pneumonitis: A Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor-induced pneumonitis is a serious immune-related adverse event managed primarily with systemic corticosteroids, yet the optimal taper duration needed to prevent relapse remains uncertain. High rates of recurrence during or shortly after taper completion continue to complicate clinical care. This systematic review and meta-analysis evaluate the pooled relapse rate following corticosteroid therapy and compare outcomes between fixed short-term tapers and individualized or longer taper strategies. A systematic search of the published literature identified studies reporting quantifiable relapse events after corticosteroid taper for pneumonitis. Six cohorts from four studies, totaling 296 patients, met eligibility criteria. The pooled relapse proportion (estimated event rate) was calculated using a random-effects model with logit transformation. Comparative analysis between taper strategies was performed using a fixed-effects model, and sensitivity analyses were conducted to evaluate robustness. The pooled relapse rate was 25.8%, indicating that approximately one in four patients experienced recurrence after corticosteroid treatment. Fixed six-week taper cohorts demonstrated significantly higher odds of relapse compared with variable or extended taper regimens. Sensitivity analysis, which excluded a low-event cohort, confirmed this association and reduced heterogeneity. Qualitative synthesis showed that certain clinical features, including the organizing pneumonia radiographic pattern and pneumonitis occurring after durvalumab therapy, frequently required tapers extending beyond twelve to seventeen weeks to achieve stable remission. Approximately one quarter of patients treated for immune checkpoint inhibitor-induced pneumonitis experience relapse after corticosteroid therapy. Fixed short-term tapers are associated with significantly higher recurrence risk compared with individualized or longer taper strategies. These findings support a risk-stratified approach to taper duration, emphasizing the need for extended tapers in higher-risk clinical scenarios while monitoring for steroid-related adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.